Hepatocellular carcinoma after danazol therapy.

Weill Bj, Menkès Cj, Catherine Cormier, A Louvel, Maxime Dougados, D Houssin
In: The Journal of rheumatology · 1988 · vol. 15(9) , pp. 1447–9 · PMID:2848945 · W2419322663
article OA: closed CC0 ⤵ 8 in-corpus citations
View on OpenAlex View on PubMed
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-08-05 ⓘ

This report describes a hepatocellular carcinoma discovered in a patient with SLE after four years of danazol therapy, suggesting ultrasound screening for early detection.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Danazol, an inhibitor of pituitary gonadotropin, has been proposed in the treatment of systemic lupus erythematosus (SLE). We report the case of a female patient with SLE in whom a hepatocellular carcinoma was discovered after 4 years of treatment with danazol. Except for 3 days of hypochondrium pain, there were neither clinical signs of liver tumor nor biological abnormalities. An ultrasonography showed 2 tumors of the liver. At histological examination after surgery, one of the tumors was found to be a benign adenoma, while the other was a well differentiated hepatocellular carcinoma. When longterm danazol therapy is required, ultrasonography may be useful for early tumor detection.

My notes (saved in your browser only)

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

Cited by (7)

Source provenance

openalex
last seen: 2026-05-10T11:36:21.069916+00:00
License: CC0 · commercial use OK